Table 7 Incidences of adjudication-confirmed cases of pancreatitis and prespecified hypersensitivity adverse events in the APaT population; Treatment Period + all follow-up days
Patients, n (%) | Omarigliptin N = 2092 | Placebo N = 2100 |
|---|---|---|
With pancreatitis | ||
Acute | 6 (0.3) | 3 (0.1) |
Chronic | 0 (0.0) | 1 (<0.1) |
With hypersensitivity | ||
Angioedema | 4 (0.2) | 1a (0.1) |
Asthma–bronchospasm | 2 (0.1) | 2 (0.1) |
Anaphylaxis | 0 (0.0) | 1 (<0.1) |